Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX, page-26

Excellent!

It could hardly get better than this. Complete safety/zero toxicity AND very significant efficacy even though this was only the mid range dose, with two patients from the low dose Cohort 1 still alive. And this is in "patients who have progressed after previous treatment with checkpoint inhibitors including Keytruda®, Opdivo® or Tecentriq®"

Now we progress to Cohort 3 and the high dose, including a trial arm at the Mayo Clinic. This is the kind of result that gets noticed, and the involvement of the Mayo Clinic will certainly boost that attention and the credibility of Imugene.

Marvellous!

I expect a good day ahead, and even better times to come!

Cheers

Dave